Trilogy appoints natural products head Angela Buglass as new CEO
Angela Buglass joined Trilogy last year and will take over the company's top job on July 1.
Angela Buglass joined Trilogy last year and will take over the company's top job on July 1.
Trilogy International [NZX:TIL], the skincare products and scented candle maker, has appointed its head of natural products Angela Buglass as its next chief executive, effective from July this year.
Buglass joined Trilogy last year after senior roles in the beauty and skincare industry at Estee Lauder and L'Oreal Group, and will take over the company's top job on July 1, Trilogy said in a statement. Her appointment is to support the company's growth in international markets, chairman Geoff Ross said.
"With the New Zealand and Australian markets both performing well and profitably now, our strategy is around pursuing growth in our key international markets, including the UK, Asia and the United States," Ross said. "We seen an opportunity to leverage Angela's direct, hands-on experience growing brands in these markets, and feel she will now be best positioned to achieve this from the CEO's chair."
Last month the Auckland-based company forecast net profit to rise to more than $4 million in the 12 months ended March 31 from $1.26 million a year earlier, with sales rising more than 18 percent to more than $35 million.
Buglass replaces Stephen Sinclair, who will stay on in an executive capacity for six months to help with her transition, and focus on key commercial and operational areas. Sinclair took over the CEO role in 2012, replacing Geoff Ross, who went to head up another of the Business Bakery's investments, Moa Group.
The Business Bakery is the investment vehicle for 42 Below Vodka founders Ross, Sinclair and Grant Baker, which they used to underwrite Ecoya's $10.1 million initial public offering in 2010.
Trilogy founder and director Sarah Gibbs also announced her intention to resign from the board after three years, though will retain her shareholding at its current 5.19 percent level.
Shares of Trilogy rose 1.1 percent to 95 cents, and have gained 31 percent this year.
(BusinessDesk)